tiprankstipranks
Advertisement

IDHQ - ETF AI Analysis

Compare

Top Page

IDHQ

Invesco S&P International Developed High Quality ETF (IDHQ)

Rating:64Neutral
Price Target:
IDHQ, the Invesco S&P International Developed High Quality ETF, earns a solid overall rating thanks to several high-quality leaders like Novartis, ABB, and ASML, which show strong financial performance, healthy growth prospects, and generally supportive technical trends. The fund also benefits from other resilient holdings such as Roche and GSK, though some positions like Rolls-Royce and Unilever introduce risks tied to financial stability concerns, bearish momentum, or rich valuations. Investors should note that a meaningful portion of the portfolio is in large international healthcare and industrial names, so sector and valuation risks in these areas are key factors to watch.
Positive Factors
Strong Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
High-Quality Leading Holdings
Several of the largest positions, including major technology and industrial names, have delivered strong year-to-date performance that supports the fund’s returns.
Broad International Diversification
Holdings spread across many developed countries and sectors help reduce the impact of weakness in any single market or industry.
Negative Factors
Moderate Fee Level
The expense ratio is not especially low, so costs may be higher than some cheaper index ETFs and can slightly reduce long-term returns.
Sector Concentration in Industrials and Financials
A large share of assets in industrial and financial companies means the fund could be more sensitive if these sectors face a downturn.
Exposure to Some Lagging Top Holdings
A few of the largest positions, such as certain financial and consumer stocks, have shown weaker year-to-date performance that can drag on overall results.

IDHQ vs. SPDR S&P 500 ETF (SPY)

IDHQ Summary

IDHQ is an ETF that follows the S&P Quality Developed Ex-U.S. LargeMidCap Index, focusing on high-quality companies in developed countries outside the U.S. It holds well-known names like ASML Holding and Novartis, and invests across many sectors, including industrials, technology, and health care, with large exposure to markets such as Japan, the UK, and Switzerland. Someone might invest in IDHQ to diversify beyond the U.S. and seek long-term growth from financially strong international companies. A key risk is that international stock prices can go up and down with global markets and currency movements.
How much will it cost me?The Invesco S&P International Developed High Quality ETF (IDHQ) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a specialized strategy of selecting high-quality international companies. The added cost reflects the fund's meticulous approach to targeting financially strong firms.
What would affect this ETF?Positive drivers for IDHQ include potential growth in developed markets outside the U.S., particularly in sectors like healthcare and technology, which are heavily weighted in the ETF and often benefit from innovation and stable demand. However, negative factors could arise from global economic slowdowns, regulatory changes in key regions, or currency fluctuations that impact international companies' profitability. The ETF's focus on high-quality companies may help mitigate risks but does not eliminate exposure to broader market challenges.

IDHQ Top 10 Holdings

IDHQ leans heavily on non-U.S. blue chips, with a clear tilt toward health care and industrial powerhouses. ASML and Advantest are the tech engines, still rising over the past few months despite some recent choppiness, giving the fund a helpful semiconductor breeze. On the defensive side, Novartis and GSK have been steady climbers, while Roche feels more like it’s stuck in neutral. Industrial names like ABB are quietly pulling their weight, but Rolls-Royce and Safran have been lagging, occasionally acting as a drag on overall performance.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV6.00%$43.18M€463.19B121.59%
76
Outperform
Novartis AG4.29%$30.90MCHF221.23B46.07%
80
Outperform
Roche Holding AG3.91%$28.17M$317.24B37.48%
73
Outperform
Advantest3.44%$24.79M¥17.59T256.42%
75
Outperform
Rolls-Royce Holdings2.94%$21.18M£107.34B83.66%
71
Outperform
SAFRAN SA2.74%$19.73M€130.54B56.03%
67
Neutral
Allianz2.59%$18.67M€143.18B19.92%
67
Neutral
ABB Ltd2.33%$16.77MCHF127.66B77.94%
78
Outperform
GlaxoSmithKline2.26%$16.27M£84.92B68.12%
77
Outperform
Unilever2.09%$15.03M£93.91B
72
Outperform

IDHQ Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
37.13
Positive
100DMA
36.05
Positive
200DMA
34.45
Positive
Market Momentum
MACD
-0.21
Negative
RSI
60.19
Neutral
STOCH
85.04
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDHQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.76, equal to the 50-day MA of 37.13, and equal to the 200-day MA of 34.45, indicating a bullish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 60.19 is Neutral, neither overbought nor oversold. The STOCH value of 85.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDHQ.

IDHQ Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$682.10M0.29%
64
Neutral
$996.82M0.24%
64
Neutral
$954.30M0.50%
63
Neutral
$612.46M0.59%
60
Neutral
$612.34M0.39%
64
Neutral
$425.17M0.39%
64
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDHQ
Invesco S&P International Developed High Quality ETF
37.76
9.85
35.29%
DFSI
Dimensional International Sustainability Core 1 ETF
SEIE
SEI Select International Equity ETF
FYLD
Cambria Foreign Shareholder Yield ETF
TLTD
FlexShares Morningstar Developed Markets ex-US Factor Tilt
MFDX
PIMCO RAFI Dynamic Multi-Factor International Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement